Vitestro is turning autonomous blood draws into a supervised clinical workflow layer

Vitestro raised $70 million in Series B financing on March 10, 2026, after receiving European CE marking for its Aletta autonomous blood-drawing device in 2024. Strategic healthcare investors in the round included Labcorp Venture Fund, Mayo Clinic, and Sutter Health, giving the financing a stronger clinical-market signal than a general medical robotics round.

Aletta performs the diagnostic blood draw workflow from tourniquet placement to bandage application. The device uses multimodal vein imaging and Doppler confirmation before needle insertion, then handles tube changing and inversion during collection. Vitestro says one trained supervisor can oversee up to three Aletta devices, framing the product as supervised clinical automation rather than fully unattended phlebotomy.

The regulatory sequence is material. Vitestro received CE marking under the European Medical Device Regulation, then planned a limited market release across selected European hospitals and clinical laboratories before broader production scale-up. For blood collection, the deployment challenge is not only needle placement; hospitals need patient acceptance, staff workflow fit, device uptime, safety documentation, training, and integration with laboratory operations.

The public clinical evidence gives the company a real base. Vitestro reports EU A.D.O.P.T. trial results with a 94.5% first-stick success rate, and patient-facing material says 90% of patients rated pain as similar to or lower than manual blood collection. CORDIS reporting for the Horizon Europe VD-1 project records the first 1,400 enrolled patients across four European hospital laboratory sites and notes that Vitestro developed the technology in-house with seven patents.

The competitive field includes manual phlebotomy services, hospital laboratory automation, BD-style blood collection systems, venipuncture-assist devices, and other robotic blood-draw research efforts. Vitestro's distinction is an integrated supervised device with CE marking, trial data, and strategic healthcare investors rather than a vein-finding accessory or lab prototype.

Public material still does not show installed fleet count by hospital, customer retention, reimbursement economics, unit economics, device uptime by clinical site, draw-cycle throughput, or post-market intervention logs. The Series B positions Vitestro around the staffing and reliability problem inside routine diagnostics. If Aletta scales through supervised clinical workflows without increasing patient friction, Vitestro becomes a hospital labor-capacity tool for one of healthcare's most common procedures.

Have a robotics update Korthos should review? Send news, deployments, product releases, funding rounds, research, or media to tips@korthos.xyz or reach out on X at @agkorthos.